AstraZeneca PLC (AZN) fair value analysis

Nasdaq · Updated 2026-09-07

AstraZeneca PLC is a pharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across multiple therapeutic areas including oncology, cardiovascular, respiratory, and infectious diseases. The company operates globally with a presence in numerous countries across North America, Europe, Asia, and other regions worldwide.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, AZN is trading at more than a 25% discount to estimated fair value.

AZN currently ranks #6 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $156.93
Sector: Healthcare
12-month range: $156.93–$202.39

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The bottom quarter of its range
DCF cross-check: Undervalued

What our data shows for AZN

Our model validated 15 trailing price-to-earnings windows for AZN, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $156.93–$202.39.
The 14-day relative strength index sits at a neutral 50.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for AZN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent AZN news

TickrTrends' derived news-sentiment signal for AZN is currently mixed, computed from recent coverage.

AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress - Slideshow (NYSE:AZN) 2026-09-08 (seekingalpha.com, 2026-09-08)
TickrTrends take: AstraZeneca's presentation at the European Respiratory Society Congress provides an opportunity to assess the clinical and commercial pipeline progress that underpins its current undervalued status in TickrTrends analysis. For valuation-focused investors, the key consideration is whether the respiratory assets presented support the thesis that AZN is trading below intrinsic value relative to its Healthcare sector peers. Such conference presentations typically reveal development timelines and competitive positioning that may justify or challenge the undervalued designation assigned by valuation metrics.
AZN Looks 10.4% Undervalued on GF Value™ as Dividend Sustainability Shines (gurufocus.com, 2026-09-05)
TickrTrends take: AstraZeneca trades at a valuation discount according to GuruFocus metrics, which aligns with TickrTrends' current undervalued assessment for the Healthcare sector company. The sustainability of the company's dividend payments represents a factor supporting the current valuation perspective, as consistent capital returns can indicate financial stability and cash generation capacity. Investors focused on valuation multiples should monitor whether AZN maintains its dividend coverage ratios and whether the stock's valuation gap persists as earnings and market conditions evolve.
US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know (livemint.com, 2026-09-05)
TickrTrends take: AstraZeneca received FDA approval for Etcamah, a new breast cancer treatment, which expands its oncology portfolio and potential revenue streams in a high-demand therapeutic area. Given TickrTrends' current undervalued assessment of AZN, investors focused on valuation should monitor how this approval translates into near-term sales figures and long-term market penetration in the competitive breast cancer treatment segment. The commercial success of Etcamah could be a material factor in validating or adjusting the current undervaluation thesis for the Healthcare sector company.

What people are saying

Follow the AZN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # AZN Weekly Indicator Summary AZN's momentum indicator has moved from an A rating to none this week, representing a notable shift in the stock's technical picture. The Healthcare sector company remains valued as Undervalued according to TickrTrends' current valuation assessment, despite the weakening momentum signal.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is AZN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), AZN is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is AZN's TickrTrends verdict?

AZN's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does AZN compare to other Healthcare stocks?

AZN ranks #6 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is AZN overbought or oversold?

AZN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

AZN vs ADMA · AZN vs ALGN · AZN vs ASTH · AZN vs BSX · AZN vs EMBC